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Abstract  
 
Eltrombopag (ELT) is a thrombopoietin receptor agonist, also reported to decrease labile iron 
in leukemia cells. Here we examine the previously undescribed iron(III)-coordinating and 
cellular iron-mobilizing properties of ELT. We find a high binding constant for iron(III) (log 
β2=35). Clinically achievable concentrations (1µM) progressively mobilised cellular iron 
from hepatocyte, cardiomyocyte and pancreatic cell lines, rapidly decreasing intracellular 
ROS and also restoring insulin secretion in pancreatic cells. Decrements in cellular ferritin 
paraleled total cellular iron removal, particularly in hepatocytes. Iron mobilisation from 
cardiomyocytes exceeded that obtained with deferiprone, desferrioxamine or deferasirox at 
similar iron-binding equivalents. When combined with these chelators, ELT enhanced 
cellular iron mobilisation, this being greater than additive (synergistic) with deferasirox. Iron-
binding speciation plots are consistent with ELT donating iron to deferasirox at clinically 
relevant concentrations. ELT scavenges iron citrate species faster than deferasirox, but 
rapidly donates the chelated iron to deferasirox, consistent with a shuttling mechanism. 
Shuttling is also suggested by enhanced cellular iron mobilisation by ELT when combined 
with the otherwise ineffective extracellular hydroxypyridinone chelator, CP40.  We conclude 
that ELT is a powerful iron chelator that decreases cellular iron and further enhances iron 
mobilisation when combined with clinically available chelators.   
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Key points  
 
• Eltrombopag is a powerful iron chelator, mobilising iron, ferritin, reducing ROS and 
restoring insulin production at clinically achievable levels. 
• Eltrombopag enhances cellular iron chelation when combined with clinically 
available iron chelators through the shuttling of iron(III). 
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INTRODUCTION 
 
Eltrombopag (ELT) is an orally bioavailable small molecular thrombopoietin receptor (TPO-
R) agonist, approved for the treatment of Idiopathic Thrombocytopenia (ITP) and 
thrombocytopenia associated with chronic hepatitis C. An under-appreciated property of ELT 
is its binding to metal ions and in particular to iron(III). Oral consumption of ELT with 
calcium-, aluminium-, and magnesium-containing foods reduced absorption of these metals 1, 
2
 and this could be due to chelation of metal ions 1. ELT also decreased labile iron within 
leukemia cells3 which could be relevant to its antiproliferative and apoptotic effects in acute 
myeloid leukemia3, 4, as well as the treatment of hepatocellular carcinoma5. In principle, some 
beneficial effects on hematopoiesis in myelodysplastic syndrome (MDS)6 and aplastic 
anemia7, 8 could also derive from iron chelation. Our preliminary findings suggested that low 
ELT concentrations could mobilise cellular iron9, 10. ELT might therefore have a role to treat 
iron overload conditions, either alone or when combined with clinically licensed chelators.  
However, little is known about the iron-binding properties of ELT.  Unknowns include the 
iron-coordination mechanism, iron(III)-binding constant, effects on iron-induced reactive 
oxygen species (ROS), effects on storage iron, relative interaction with different cell types, 
and mechanisms of interaction with other chelators.    
 
Iron chelation therapy is used to treat transfusional iron overload in thalassemias, sickle cell 
disease and MDS.  Non-transfusional iron overload may also be treated with iron chelation.  
While three iron chelators are now licensed, the removal of excess iron is slow and treatment 
can also be limited by chelator toxicity, particularly at higher doses. Therefore combinations 
of chelators have been used to enhance chelation. While simply additive effects can be 
valuable, true synergism, where one chelator increases the rate of access of a second chelator 
to iron pools, would be valuable11.  
 
The ability of an iron chelator to mobilize cellular iron is related to the iron-binding constant 
and the ability of the iron chelator to enter cells11. Thus, chelators with low lipid solubility, or 
large molecular weight, enter cells slowly and have little effect on iron release12. These same 
properties also affect iron release in animal models13, as well as affecting their access to 
intracellular iron pools14, including metalloenzymes15, 16, cell cycle, growth17 and apoptosis18.   
The two largest chelateable iron pools are, firstly, within hepatocytes where over 70% of 
body iron is deposited and, secondly, iron released from macrophages after catabolism of red 
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cells19. The most rapidly chelateable iron pool within cells is the so-called labile iron pool 
(LIP), which is relatively small at any moment and is predominantly contributed to by 
intracellular ferritin catabolism19, 20.  
 
In this paper we have investigated the iron-binding properties of ELT, its ability to mobilize 
intracellular iron and to decrease ROS-mediated cellular damage, using a recently described 
cell culture model11. Chelators can be metabolically inactivated at their iron-binding sites, 
particularly in hepatocytes, but with wide interspecies variability, and where metabolism in 
rodents, and hence chelator efficacy, can differ significantly from humans21, 22. In vitro 
screening therefore ideally needs to include human-derived cells. We have included a human 
hepatoma cell (HuH7) as the primary screen, as drug metabolism is well described and has 
the advantage of stability in culture, whereas primary cells can lose key metabolism enzymes 
within hours of isolation. Iron overload in myocardium and endocrine system is 
quantitatively much smaller than in the liver, but damage is clinically important, causing fatal 
cardiomyopathy and type-I diabetes, respectively. We have therefore also investigated cell 
lines derived from these cells. Decrements in total cellular iron and ferritin induced by ELT, 
have been compared with clinically licensed chelators. We have also examined whether ELT 
diminishes iron-induced intracellular ROS and thereby restores cell function. We have 
investigated whether additional iron chelation can be achieved by combining ELT with other 
chelators, and examined the mechanisms by which this occurs.  
 
MATERIALS AND METHODS  
 
Spectrophotometric method for pKa and iron stability constant  
An automated titration system20 was utilized under the conditions of constant temperature at 
25°C and constant ionic strength at 0.1M, using 0.1M KCl, 0.1M HCl and 0.1M KOH. The 
pH electrodes were calibrated using the GLEE program23. The titration data were analysed 
using the pHab program24. Species plots were calculated using the HYSS program25. 
Analytical grade reagent materials were used in all solutions. 
 
Determination of kinetics of iron binding to ELT, DFX and CP40.   
These were performed spectrophotometrically, using difference spectra where necessary, 
with a Varioscan Flash plate reader (UK). Kinetic data were plotted using absorbance for 
ELT or DFX2Fe complexes. Wavelengths chosen for kinetic analysis were determined from 
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spectral plots of ELT, DFX, and their respective iron complexes. Buffered ferric citrate was 
prepared26 using concentrated MOPS pH 7.4. Eltrombopag was prepared as a 1% solution in 
DMSO. ELT-iron complexes were prepared as follows: ELT/DMSO aliquot was mixed with 
ferric chloride atomic standard solution added at desired molar ratios. pH was increased by 
adding 1M MOPS pH 7.4.  Deferasirox 1% solution was prepared in DMSO.  ELT in culture 
media was diluted to ensure final concentration of DMSO <1%.  
 
The cellular models and iron measurements  
The human hepatocarcinoma (HuH7) and rat cardiomyocyte (H9C2) cell lines were 
purchased from Sigma-Aldrich UK.  RINm5F rat pancreatic cell line, which secretes insulin 
following a glucose challenge, was from LGC ATCC Sales, UK. H9C2 and HuH7 cells were 
plated, cultured and iron-loaded as recently described9, 11. Iron loading was obtained by 
serially treating cells with 10% Fetal Bovine Serum (FBS)-RPMI media over two ten-hour 
periods. Increments in cellular iron differed between cell types (threefold in HuH7: a twofold 
in H9C2 and fourfold in RINm5F cells). Cell washing, chelator exposure and measurement of 
cellular iron using ferrozine assay, adjusted for cellular protein, was as described11. Iron 
release was performed in serum-free medium, as FBS contained free iron that bound 
chelators extracellularly, decreasing efficacy. Reports of ELT inhibition by serum4 are more 
likely a consequence of iron contamination in FBS than protein binding to ELT  (see 
supplementary data).  
Cell damage and viability, utilized the ‘LDH Cytotoxicity Detection Kit’ (Takara Bio Inc). 
Human and rat tissue ferritin of cell lysates were measured by enzyme-linked immunosorbent 
assay (ELISA) kits (Cusabio, Wuhan, China and My BioSource, San Diego, USA 
respectively). Desferrioxamine (DFO), Deferiprone (DFP) and Deferasirox (DFX) were 
purchased from Sigma-Aldrich, UK and ELT from Generon, UK. 
 
Detection of Reactive Oxygen Species  
A cell-permeable oxidation-sensitive fluorescent probe 5,6-carboxy-2’,7’- 
dichlorofluoresceindiacetate (DCFH-DA) (Molecular Probes, Leiden, Netherlands) was used, 
where non-fluorescent DCFH-DA is hydrolyzed to DCFH inside of cells, yielding highly 
fluorescent DCF in the presence of intracellular hydrogen peroxide (H2O2).  Cells plated in 
Corning 24-well plates (Sigma-Aldrich, MA, USA) were pre-incubated with 4mM HDCF-
DA for 30 minutes at 37°C. Chelators were then added, and fluorescence recorded 
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continuously over 90 minutes (excitation at 504nm, emission at 526nm). The time between 
the addition of chelators and commencing ROS recording was 3-5 minutes.  
 
Insulin quantification 
Following iron loading and chelator treatment, the cells were challenged with Krebs’ Ringer 
Buffer twice, for one hour at a time, containing 2.8mM and 16.7mM glucose27, 28. The 
supernatant was then collected and insulin concentration determined using a standard rat 
insulin ELISA kit (Life Technologies Limited, UK).  
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 RESULTS 
 
Iron(III)-binding and speciation plots for ELT alone or combined with other chelators  
The previously undescribed iron(III)-binding properties of ELT are key to understanding the 
effect on cellular iron mobilisation, either alone or when combined with other chelators. The 
iron-binding properties of ELT in Figure 1 and Table 1 were determined specifically for this 
communication. The log P value of ELT was derived from a computer program29. The usual 
chemical representation of ELT is shown in structure 1, lacking a high affinity iron(III)-
binding site (Figure 1A).  However ELT can be represented as a mixture of two tautomers; 
the second (2) possessing a potential tridentate iron(III)-binding site. The 1:1 complex (3) 
possesses zero net charge (Table 1) and has a molecular weight <500, similar to the DFP-
iron complex. The speciation plot for iron(III)/ELT (Figure 1B) indicates a mixture of the 
1:1 and 2:1 complexes at pH 7.4.  Figure 1 (C, D, E) shows speciation plots of iron(III) 
(1µM) binding at increasing concentrations of ELT (1-10µM) in the presence of DFO 1µM, 
DFP 3µM and DFX 2µM. These predict proportions of iron bound to ELT or a second 
chelator, after reactions have proceeded to completion. Thus, for example, at 1µM ELT over 
99% of iron(III) will be bound to DFO (A), whereas about half of the iron will be bound to 
DFP (B) and about 70% to DFX (C). These values are helpful in interpreting iron-release 
studies using combinations of ELT with a second chelator but do not predict the rates at 
which reactions proceed.  
 
ELT decreases cellular iron in cardiomyocyte and hepatocyte cell lines 
Mobilisation of total cellular iron from HuH7 cells was examined between 1 and 30µM ELT 
at 8h (Figure 2A). These are clinically relevant as Cmax plasma concentrations of 8, 18, and 
28μΜ, have been reported at 30, 50, and 75 mg/day30.  In cardiomyocytes, as little as 1μΜ 
ELT achieved significant mobilisation after only 1 hour (Figure 2B). A 2:1 binding of ELT 
to iron(III) (Figure 1 and Table 1) implies 0.5µM iron-binding equivalents (IBE) at 1µM 
ELT. Comparison of iron mobilisation by 1µM ELT with DFP, DFO and DFX in HuH7 or 
H962 cardiomyocytes is shown in Table 2 (top 4 rows).  In HuH7, ELT was less effective 
than DFP, DFX, and DFO at 1µM. In contrast to the lower efficacy of ELT than other 
chelators in HuH7 cells, 1µM ELT mobilised more iron than DFO, DFX or DFP in H9C2 
cells (Table 2). The relevance of ELT metabolism to its relative efficacy in HuH7 and H962 
is discussed below.  
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 As cell viability could influence iron release independently of chelation, experiments were 
only performed where baseline viability exceeded 98%, as assessed by the LDH assay. 
Hepatocytes showed no signs of toxicity following 8 hours of ELT treatment up to 30μΜ. By 
contrast, cardiomyocyte viability after 8 hours of exposure to 30μΜ ELT fell to 93%. Thus 
some iron release in cardiomyocytes at 30µM (Figure 2B) could be partially attributed to 
toxicity.  
 
ELT decreases cellular ferritin   
We next wished to determine how changes in total cellular iron were paralleled by changes in 
cellular ferritin. When cells were iron-loaded (see methods), tissue ferritin increased by 75% 
in HuH7 and by 33% in H9C2. After treatment with 10µM ELT for 8 hours, 85% ferritin 
reduction was seen in HuH7 and 46% in H9C2 cells (Figure 2C, D). Respective decrements 
in cellular iron were 25% in HuH7 and 65% in H9C2 cells.  Thus ELT decreased total 
cellular iron and cellular ferritin in both cell types, with ferritin decrements being 
proportionately greater in HuH7 than H9C2 cells.  Thus ferritin in HuH7 cells appears more 
responsive, both to iron-loading and unloading than in H9C2 cells, consistent with the known 
higher iron-storage capacity of hepatocytes.   
 
ELT decreases ROS more rapidly than other chelators 
Intracellular ROS generation by iron is predominantly determined by the LIP concentration31. 
Unlike measurement of total cellular iron or ferritin, continuous real-time measurement of 
ROS is achievable, allowing insight into kinetics of chelation. In Figure 3A, B the ROS 
generation rate is rapidly decreased by ELT in HuH7 and H9C2 cells, even at the first 
measurable time-points. Inhibition of ROS by DFO was relatively slow, consistent with the 
known slow cellular uptake of DFO14, while DFP and DFX have intermediate effects. In 
Figure 3C, D, the inhibitory effects of 10µM ELT and other chelators at 10µM IBE (except 
CP40 at 33μΜ IBE) are shown in HuH7, H9C2 and RINm5F cells. ROS generation is 
inhibited with ELT by 73% in HuH7 and by 61% in H9C2 cells, more than with other 
chelators at comparable concentrations. In Table 3 (top 4 rows) ROS inhibition at 1µM is 
shown, where ELT has the greatest effect. Thus rapid ROS decrements are similar both in 
hepatocytes and cardiomyocytes, unlike iron mobilisation.  The slower mobilisation of total 
cellular iron will allow time for metabolic inactivation of ELT in hepatocytes, hence decrease 
activity of ELT in these cells. 
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Eltrombopag decreases cellular iron and reverses iron-mediated suppression of insulin 
secretion in the pancreatic β-cell line (RINm5F) 
After RINm5F cells were iron-loaded, 10µM ELT subsequently mobilised a similar amount 
of iron to 10μΜ ΙΒΕ DFO or DFX at 8 hours (Figure 2E).  ROS inhibition by ELT was 
found to be dose- sensitive, being greater at 10µM ELT than 3µM ELT (Figure 3E). When 
iron-loading was increased by increasing FBS from 10 to 25%, insulin secretion decreased 
(Figure 3F). Decrements in ROS and cellular iron were associated with restoration of insulin 
secretion (Figure 3G). This was also achieved with DFX but not with DFO or DFP.  
Restoration of cell function is presumably related to decreasing ROS, secondary to lowering 
LIP.  
 
Effects of chelator combinations with ELT on iron mobilisation or ROS inhibition 
Combinations of chelators may decrease the doses of individual chelators required for a given 
effect. When DFO, DFP, or DFX at 1µM IBE were combined with 1µM ELT, iron 
mobilisation was greater than monotherapy with either ELT or a second chelator (Table 2, 
lower 3 rows). The most effective combination was ELT plus DFX, being greater than 
additive. However ROS inhibition by ELT when combined with other chelators was never 
more than additive (Table 3, lower 3 rows).  Iron mobilisation using the combination of ELT 
(3µM) with the extracellular chelator hydroxypyridinone chelator CP40 (3µM), was also 
greater than additive (Figure 2F), suggesting that entry of a second chelator into cells is not a 
prerequisite for synergistic chelation (see discussion and Figure 5C).  
 
Mechanisms of synergistic iron removal by ELT when combined with DFX or CP40 
In a cell-free system, ELT removed iron from pre-formed iron-citrate complexes (Figure 4A) 
faster than DFX (Figure 4B) suggesting that ELT accesses some chelateable iron pools faster 
than DFX. Preformed complexes of ELT also donated iron to DFX (Figure 4C) or CP40 
(Figure 4D) more rapidly than preformed ferric citrate complexes donated iron to DFX.  
Donation to DFX was most rapid at ELT:iron ratios of 2:1 or 3:1 (Figure 4E). Thus ELT 
appears to satisfy the requirements of an iron-shuttle 36, capable of both rapid iron chelation 
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as well as iron donation to a second chelator. As DFX is known to enter cells and chelate iron 
directly32,  DFX could in principle act as a sink for chelated iron within the cells, which is 
unlikely with CP40.  
 
Greater than additive chelation with DFX or CP40 could in principle also occur by inhibiting 
re-uptake of iron from ELT complexes. In Figure 5A, ELT iron complexes donated iron to 
HuH7 cells.  This was inhibited by the extracellular chelator CP40 but not by DFX (Figure 
5A).  However, DFX complexes can also donate iron to cells (Figure 5B) whereas CP40 
does not33. This we attribute to the lipophilicity of DFX-iron complex, but the marked 
hydrophilicity of the CP40-iron complex 11,12. Figure 5C suggests a mechanistic scheme for 
cellular iron mobilisation by ELT alone, or combined with CP40. This involves cellular 
uptake of ELT and chelation of LIP, which we have not measured directly but which is 
consistent with several lines of direct and indirect evidence (see discussion).  
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DISCUSSION 
We have demonstrated progressive removal of total cellular iron by ELT in H9C2, HuH7 and 
RINm5F cell lines. This is associated with lowering of intracellular ferritin, consistent with 
decrements in storage iron (although storage iron was not measured directly). This was also 
associated with decrements in ROS and, with restoration of insulin secretion in iron-loaded 
RINm5F cells.  In H9C2 cardiomyocyte derived cells, ELT proved superior at mobilizing 
cellular iron to licensed iron chelators (DFO, DFP, and DFX), at a relatively low 
concentration.  In, the human hepatocellular HuH7 line, 1µM ELT was less effective than in 
the rat cardiomyocyte H9C2 cell line (Table 2) but was increasingly effective at higher 
concentrations (Figure 2A).  Rapid metabolism of ELT in HuH7 cells may decrease efficacy. 
ELT is metabolized by mono-oxygenation and glucuronidation, with liver conjugation 
preceding elimination in faeces and urine 34. Hepatocytes are typically more active in drug 
metabolism than cardiomyocytes, and HuH7 cells contain most of the Phase I and Phase II 
enzymes present in hepatocytes35. Thus greater metabolic inactivation of ELT would be 
expected in HuH7 than H9C2 cells. Indeed CYP2B1, 2B2, 2E1 and 2J3 are expressed at 
lower levels in H9C2 and myocardium than in hepatocytes36.  As H9C2 cells are rat- rather 
than human-derived, inter-species differences in metabolism could contribute to the observed 
differences. In clinical use however, metabolic inactivation of ELT is unlikely to be a major 
issue limiting iron chelation, as un-metabolized ELT accounts for >94% of drug at 4h with 64% 
remaining un-metabolized at 24h34. The low ELT concentrations that is effective in cell 
culture may not necessarily translate to animal and clinical studies, particularly if metabolism, 
distribution, and elimination of iron complexes differ significantly in vivo.  The effectiveness 
and doses of ELT required in vivo, alone or in combination with a second chelator, therefore 
need to be established.  
 
While we have not measured ELT entry into cells directly, we believe based on several 
independent lines of evidence that rapid cellular uptake of ELT is likely.  Firstly, ELT is 
taken up rapidly into isolated hepatocytes37 and neuronal cells38. Secondly, studies with other 
chelators, have shown that chelator entry into cells is key to cellular iron mobilisation. The 
high lipophilicity and low molecular weight of ELT (Table 1) are properties associated with 
cellular uptake and high chelator efficacy 11-14. Thirdly, rapid ROS inhibition by ELT 
supports rapid cellular uptake. ROS inhibition appears to involve direct interaction of ELT 
with ROS4, which would require intracellular uptake by ELT.  Fourthly, ELT rapidly lowers 
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labile intracellular iron3, the kinetics of which are more consistent with rapid ELT entry into 
cells than with secondary effects of iron depletion. Fifthly, the lower cellular iron 
mobilisation by ELT in HuH7 than H9C2 cells (contrasting with similar decrements in ROS) 
is consistent with greater metabolic inactivation in HuH7 cells, which itself requires 
intracellular access by ELT. 
 
Our data show greater-than-additive cellular iron mobilisation by combinations of ELT with 
either DFX or CP40, whereas additive effects are seen with DFO and DFP.  Consideration of 
iron-binding constants (pFe) and speciation plots for these chelators (Table 1) suggested that 
iron shuttling by ELT might account for the enhanced effects when combined with DFX or 
CP40. The phenomenon of iron shuttling has been described with other chelator 
combinations11, 39-41, where one chelator possessing rapid access to iron pools subsequently 
donates iron to a 'sink' chelator possessing greater stability for iron(III) binding but slower 
kinetic access.   In principle a second chelator could act as a sink for iron chelated by ELT 
either within or outside cells. While the low molecular weight and lipophilicity of ELT, both 
as a free ligand and as iron complexes, are well suited to iron shuttling across cell 
membranes42, it is not essential for the 'sink' chelator to enter cells for synergism to occur 42.  
The donation of iron from ELT complexes to CP40 extracellularly could explain why CP40, 
which has no inherent iron-mobilising effects of its own due to its inability to enter cells, 
enhances iron chelation when combined with ELT.  Indeed this mechanism has been 
described with other iron chelators in combination with CP4042. While the speciation plots in 
Figure 1B, C, D, E predict that iron will eventually be donated by ELT onto DFX or DFO, 
they provide no direct evidence for the rate at which this occurs. We therefore undertook 
additional experiments in cell-free systems.  ELT accessed citrate-bound iron faster than 
DFX (Figure 4A, B), which would accelerate net iron chelation, particularly if the iron was 
then donated to DFX as a shuttling effect.  Indeed, we found iron donation from ELT 
complexes to DFX or CP40 at rates sufficient to account for enhanced chelation (Figure 4C. 
D). However, we also found that re-uptake of iron from chelate-iron complexes needs to be 
accounted for. CP40 inhibited iron uptake from ELT complexes (Figure 5A) whereas DFX 
did not (Figure 5B).  This may relate to DFX-iron complexes themselves being taken into 
cells (Figure 5B), unlike those of CP40.   Based on these observations, and the speciation 
plot data, we have suggested an overall scheme for how greater-than-additive cellular iron 
removal may occur both extracellularly and intracellularly (Figure 5C).  In this scheme, the 
greater-than-additive iron mobilisation seen when CP40 was combined with ELT is mainly 
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achieved extracellularly by CP40 (shown as L) accepting iron chelated by ELT, allowing 
ELT to become available for further iron chelation. The iron from the CP40-iron complex is 
not taken back up into cells whereas iron can be donated by DFX complexes to cells (Figure 
5B), most of the greater-than-additive iron mobilisation obtained by combining DFX (not 
shown) with ELT occurs intracellularly, through accelerated chelation of LIP by ELT 
compared with DFX.  
 
Our data are consistent with the iron-chelating effects of ELT being independent of the TPO-
R effect because the latter is highly species-specific3, 43. The thrombopoietic actions of ELT 
occur only in humans and primates with no effect in rodents, whereas the iron mobilizing 
effects in our experiments were seen both in human HuH7 cells and rat H9C2 cardiomyocyte 
and RINm5f pancreatic cells. The chelating actions of ELT could be clinically beneficial in 
several settings. An obvious application would be the treatment of transfusional iron overload. 
The elimination route for iron complexes of ELT is currently unknown and requires studies in 
animal models and in humans. Inter-species differences in metabolism and routes of 
elimination of iron complexes are well established with other chelators and may be 
unpredictable from first principles22. However, if iron chelated by ELT is donated to a second 
chelator such as DFX, then the ELT iron complex would not need to be eliminated in urine or 
faeces directly. This will need to be demonstrated in vivo however.  
 
In addition to increasing platelet counts, ELT can increase red cell and neutrophil counts and 
is approved in the US for the treatment of severe aplastic anemia44.  Some effects of ELT on 
hematopoiesis in MDS and aplastic anemia might be derived from this iron-chelating 
mechanism. As our data suggest that ELT-iron complexes can also donate iron to cells, iron 
redistribution should also be examined as a mechanism for improved haematopoiesis.  Anti-
leukemic effects mediated through modulation of intracellular iron content have also been 
postulated3. The antioxidant and iron-chelation properties are tightly linked to cell death in 
leukemia cells3 as the anti-proliferative and apoptotic effects of chelators are well described17, 
45
, through mechanisms that include ribonucleotide reductase inhibition16. However, in 
patients with ITP, iron chelation could create or exacerbate iron deficiency, which needs to be 
explored. Importantly, the 1µM ELT concentration that mobilised cellular iron is nearly 
twenty-fold less than peak plasma concentrations obtained following 30mg ELT orally30. At 
this dose, platelet increments do not typically exceed 1.2 x baseline in healthy volunteers with 
repeat dosing46.  Hence, in principle, effective chelating doses could be given without 
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promoting unacceptable thrombocytosis, although requiring careful clinical study. In 
principle, still lower concentrations could be used when combined with a clinically licensed 
chelator. ELT has been generally well-tolerated long-term47, the most common adverse 
events being: headache, gastrointestinal symptoms, and upper respiratory tract infections47.  
Published studies did not demonstrate any correlation between ELT treatment and occurrence 
of thromboembolic events48-51. This suggests that ELT doses that induced significant 
intracellular chelation could be administered to non-thrombocytopenic patients without 
appreciable changes in platelet counts. 
 
In conclusion, we have demonstrated for the first time the iron-binding properties of ELT and 
its iron-mobilizing properties from cells in culture. Decrements in ROS and improved cell 
function were also observed. Single agent ELT mobilised intracellular iron at concentrations 
similar to or lower than clinically licensed chelators, particularly from H9C2 cells. Additive 
or synergistic intracellular chelation with clinically available chelators has been shown. It 
will be important to demonstrate whether these in vitro effects and effective doses translate to 
iron-overloaded animals and ultimately to the clinical setting.  
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FIGURE LEGENDS 
 
Figure 1.  Structure and iron-binding properties of ELT.  Data on the iron-binding 
properties of ELT were obtained specifically for this paper and are not previously published 
elsewhere. The iron-binding properties of other chelators are based on previously published 
data11, 19.  (a) Structure of ELT and its iron complexes are shown. The free ligand possesses 2 
tautomers (1 and 2). Three major iron(III) complexes have been identified: 3 (FeELT), 4 
(FeELT2H) and 5 (FeELT2). (b) The speciation of iron(III) in the presence of ELT as a 
function of pH. [Fe]total=1μM; [ELT]total=10μΜ is shown at steady state (i.e. when sufficient 
time has elapsed for the reactions to go to completion). These proportions are calculated from 
the iron-binding constants for iron-chelate complexes of the respective chelators shown in 
Table 1 and determined as described in methods.  Titration with iron(III) yielded three 
equilibrium constants: KFeL=25.6, KFeL2H=43.4, and KFeL2= 34.9.  ELT has three pKa values 
(the pH at which half the molecules are ionised) of 2.6, 8.7, 11.1. Using these data, a pFe 
value of 22.0 (the strength of iron(III) binding, being the negative log of the unbound iron(III) 
concentration under defined conditions (1µM iron(III) and 10µM chelator52) was determined, 
which is greater than that of DFP (20.4) and very similar to that of DFX (23.1). Competition 
between ELT and other chelators for iron(III) are shown for (c) 1µM DFO, (d) 3µM DFP (e) 
2µM DFX.  These show the predicted proportions of each ELT iron complex when mixed 
with a second chelator, after reactions have gone to completion (in steady state). Thus for 
example, at 1µM ELT over 99% of iron(III) will be bound to DFO (c), whereas under the 
same conditions about half of the iron will be bound to DFP (d) and about 70% to DFX (e).  
 
Figure 2.   Cellular iron mobilisation and/or ferritin iron decrements with ELT from 
HuH7, H9C2 and RINm5F cells. (a) Dose response for iron release from HuH7 cells at 8h 
is shown. (b) Dose response for iron release from H9C2 cells at 1, 2, 4 and 8 hours is shown. 
Cells were loaded with iron as described in methods.  Adherent cells were rinsed four times, 
including one wash containing DFO at 30µM IBE and 3 PBS washes, and subsequently 
exposed to ELT and other chelators for the times shown. Chelator-containing supernatants 
were then removed, and the cells washed four times as above before lysing with 200mM 
NaOH. Intracellular iron concentration was then determined at each time point using the 
ferrozine assay described in methods and normalised for total cellular protein in each well. 
Results shown are expressed as the % of T0 cellular iron released at the times shown and are 
the mean±SEM of 6 replicates in one representative experiment. (c) Iron release by ELT 
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10μΜ and DFO, DFP and DFX 10μΜ IBE following 8 hours of treatment in RINm5F cells. 
Cells were iron-loaded using two 10-hour changes of 10% FBS-containing RPMI media and 
rinsed as above. Comparison of the effect of ELT on ferritin and total cellular iron 
mobilisation in (d) HuH7 hepatocyte and (e) H9C2 cardiomyocyte cells is shown. Following 
iron loading, chelator treatment for 8 hours and rinsing, iron content was ascertained as 
described above. Ferritin was quantified using commercially available ELISA kits 
appropriate for our rat and human cell lines. Results are expressed as the % of T0 cellular iron 
mobilised or decrement of ferritin expressed as % of T0 values at the times shown and are the 
mean±SEM of 3 replicates of one representative experiment. 
 
Figure 3.  Effect of ELT and iron chelators on intracellular ROS generation and cell 
function (insulin production) in iron-loaded cells.  The time-course for ROS inhibition by 
ELT and other chelators are shown in (a) HuH7 or (b) H9C2 cells. Cells were iron-loaded 
and then rinsed four times as described above. Chelators were then added, and the rate of 
change of ROS production was recorded as fluorescence change (excitation at 504 nm, 
emission at 526 nm) continuously over 1 hour in the plate reader at 37oC. DFO, DFP, and 
DFX were used at 10μM IBE, and ELT at 10μΜ. The rate of ROS production was compared 
between chelator-treated and chelator-untreated cells. Data shown are readings from 
individual plates. ROS rate inhibition at 1h with CP40, DFO, DFP, DFX, and ELT are shown 
in (c) HuH7 and (d) Η9C2 cells at 10µM IBE for each chelator and 10µM ELT and 33µM 
IBE CP40.  10µM ELT shows greater inhibition of ROS in both cell types than other 
chelators at the same concentration in both HuH7 and H9C2 cells. The extracellular 
hydroxypyridinone chelator, CP40, had no effect on ROS. (e) Effect of chelator treatment 
over a 90-minute period in RINm5F cells on ROS generation is shown. Results are the 
mean±SEM of 4 observations in one experiment. (f) Effect of iron loading in RINm5F cells 
with two changes of RPMI media containing 10-25% FBS on insulin secretion. Following 
treatment, cells were challenged with Kreb’s Ringer Buffer containing glucose and insulin 
concentration in the supernatant determined as described in methods. (g) Effect of chelation 
treatment on insulin production in RINm5F cells iron-loaded with two 10-hour changes of 
RPMI media containing 25% FBS. (* p<0.05, ** p<0.01 compared to control). Results are 
the mean ± SEM of 3 observations in one experiment. 
 
Figure 4.  Rates of iron chelation and exchange between ELT and DFX in vitro 
The rates of ferric-chelate complex formation from preformed ferric-citrate complexes (iron: 
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citrate 10:100µM) are shown with either (a) ELT (30µM), (monitored at 614nm which form 
a secondary peak of ELT-Fe complex), or (b) DFX (30µM) (monitored at 556nm, secondary 
peak for DFX-iron complex). The top horizontal line represents 100% iron complex 
formation of ELT or DFX (10µM iron(III)). The lower horizontal lines represent the 
absorbances of the iron-free ligands (30µM). It can be seen that ELT binds iron from ferric 
citrate complexes faster than DFX. The 50% effect is achieved at about 180 min for ELT, but 
later at around 300 min for DFX.  The 100% effect is achieved by ELT at about 12 hours 
whereas DFX takes approximately 33 hours. (c) The rates of ferric-DFX complex formation 
(300µM of DFX) from either preformed ferric-citrate (iron:citrate 10:100µM) or from ferric-
ELT (10µM, 1:2) is shown. It can be seen that DFX binds iron from preformed complexes of 
ELT faster than from ferric-citrate complexes (d) Rate of CP40 ferric complex formation is 
shown (at 200µM IBE CP40 from preformed 10µM FeELT2. The reaction is completed at 
approximately 200 minutes. (e) The effect of excess ELT ratio to iron on the rate of DFX 
chelation from preformed iron(III):ELT complexes (ratios 1:1 , 1:2, 1:3  and 1:10) and 3.33, 
6.66, 10, 33.3µM ELT, respectively) are shown.  Iron complexes of DFX form more rapidly 
and most completely when the ratio is 1:2 and 1:3 than with ratios of 1:1.  A 10-fold excess 
of iron-free ELT to iron retards the rate of iron donation to DFX.  
 
Figure 5.  Cellular uptake of iron complexes of ELT, interactions with DFX and CP40 
and proposed mechanisms of interaction of ELT with chelatable cellular iron and 
effects of second chelator.  Iron uptake into HuH7 cells from preformed chelate complexes 
of ELT or DFX is shown at 6h, in panels (a) and (b) of the same experiment.  Control iron 
release with ELT or CP40 (a) or DFX alone (b) are also shown. CP40 was chosen for 
evaluation because of its lack of iron removal from cells when used as a single agent and its 
lack of iron donation to cells.   After incubation, cells were washed, the first wash containing 
DFO at 30µM IBE and then with 3 PBS washes before intracellular iron concentration was 
determined using the ferrozine assay as described in the methods. (a) Iron uptake from 
chelate complexes of ELT is shown, where complexes of ELT were presented either as 1:1 or 
1:2 ratios of iron:ELT.  CP40 inhibits iron uptake from both FeELT and FeELT2.  (b) In 
contrast to CP40, DXF does not inhibit the net uptake of iron from preformed complexes of 
ELT. Preformed complexes of DFX (DFX2Fe) donate some iron to cells but less than from 
complexes of ELT.  (c) Proposed mechanisms of interaction of ELT with cellular iron with or 
without a second chelator.  ELT diffuses into cells, rapidly binding LIP iron thus decreasing 
ROS. Iron complexes of ELT then diffuse out of the cell, some of which can subsequently 
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donate iron back to the cell (Figure 5A). Diffusion of ELT into cells was not measured 
directly but has been previously shown in other cells and is consistent with its low molecular 
weight, its high lipid solubility and rapid intracellular ROS inhibition.   A second chelator (L) 
can increase intracellular iron chelation and thus cellular iron release if it gains direct access 
to LIP, as is known to occur with DFX but not with CP40. ELT binds chelateable iron (from 
citrate) faster than DFX (Figure 4A and B).  DFX binds iron from complexes of ELT faster 
than those bound to citrate (Fe:citrate 10:100) (Figure 4C).  A second chelator can also 
increase net iron release extracellularly by competitive removal of iron from ELT-iron 
complexes, thus decreasing the donation of iron from ELT-iron complexes to cells. Both 
intracellular and extracellular donation of iron to a second chelator (L) potentially frees up 
ELT for a further round of iron chelation.   
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TABLES 
 
Table 1. Comparison of the structure and iron-binding properties of ELT and other chelators.  
Binding properties of ELT are not previously described and were determined specifically for 
for this paper. The relative stabilities of iron(III) binding are represented by the pFe, where 
the pFe of a given chelator for iron(III) is the negative log of the uncoordinated metal 
concentration under defined conditions53. The higher the pFe values, the lower the 
concentration of uncoordinated iron(III) and hence the greater stability for the iron-chelate 
complex. ELT can form neutrally charged 1:1 complexes with iron(III) or 3- negatively 
charged 2:1 complexes.  Properties of other chelators use published data11,19, except for the 
pFe value of DFX where 23.1 is used based on the properties of the molecule in 100% water; 
The widely adopted values of 22.4 or 22.5, are based on titrations run in 20% DMSO. When 
pairs of chelators are combined in solution,  iron(III) will bind preferentially to the chelator 
with the higher pFe value. This is highest for DFO and lowest for DFP, with DFX having an 
intermediate value but greater than ELT. DFO, desferrioxamine; DFP, deferiprone; DFX, 
deferasirox; Kpart, partition coefficient54-56. 
 
Table 2. Comparison of percentage of intracellular iron mobilised at 8hours in a 
cardiomyocyte (H9C2) and a hepatocyte (HuH7) cell lines by clinically available chelators or 
ELT, alone (top panel) or in combination (lower panel). Chelator concentrations are 
expressed as iron-binding equivalents (IBE). Cells were pre-loaded with iron, rinsed, 
incubated with chelators, and cellular iron determined as described in Figure 2. Results 
shown as the % iron released expressed as a % of T0 cellular iron and are the mean±SEM of 4 
replicates in one experiment. 
 
Table 3. Comparison of ROS generation in cardiomyocyte (H9C2) and a hepatocyte (HuH7) 
cell lines is shown after addition of clinically available chelators or ELT, alone (top panel) or 
in combination (lower panel) over 90 minutes.  Experimental design and determination of 
ROS is otherwise as described in Figure 3. Results are the mean±SEM of 4 observations in 
one experiment. (* p<0.05, ** p<0.01 compared to control). 
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DFO DFP DFX Eltrombopag
Molecular weight 561 139 373 442
Chelator / Iron(III) ratio 1:1 3:1 2:1 2:1 and 1:1
Log stability constant for 
iron (III)
30.6 37.2 36.5 34.9
pFe (pmol/L) 26.6 20.7 23.11
22.0
Charge of free ligand pH 
7.4
1 + 0 1- 1-
Charge of iron complex at 
pH7.4
1+ 0 3- 3- (2:1); 0 (1:1)
Lipid solubility free ligand 
(log P)
-3 -0.8 4.3 6.3
1 Value determined for 100% aqueous system
TABLE 1
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Table 2
% iron release following 8 hours of chelator treatment
H9C2 
Cardiomyocyte-
like cells
HuH7 
Hepatocyte-
like cells
DFO 1μM ibe 14.2± 1.2 28.6 ± 1.4
DFP 1μM ibe 17.1± 1.5 25.7± 1.2
DFX 1μM ibe 11.7 ± 1.0 22.8 ± 1.7
ELT 1μM 42.1 ± 2.1 6.9 ± 0.3
ELT 1μM + DFO 1μM ibe 58.2 ± 2.5 34.3 ± 1.1
ELT 1μM + DFP 1μM ibe 59.9 ± 3.1 38.2 ± 1.5
ELT 1μM + DFX 1μM ibe 66.4 ± 2.4 51.4 ± 1.9
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% decrease in ROS generation rate at 90 minutes
H9C2 
Cardiomyocyte–
like cells
HuH7      
Hepatocyte–
like cells
DFO 1μM ibe 12.1  ± 1.3 14.3  ± 0.9
DFP 1μM ibe 29.7  ± 1.3 25.0  ± 1.8
DFX 1μM ibe 33.2  ± 2.7 21.4  ± 2.6
ELT 1μM 42.2  ± 1.7 39.2  ± 2.1
ELT 1μM + DFO 1μM ibe 62.2  ± 3.2 55.1  ± 3.1
ELT 1μM + DFP 1μM ibe 60.3  ± 4.1 60.2  ± 3.2
ELT 1μM + DFX 1μM ibe 57.3  ± 3.3 51.3  ± 2.2
Table 3 
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